combretastatin has been researched along with Cancer of the Thyroid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhakta, S; Cooney, MM; Flick, SM; Gilkeson, RC; Greskovich, JF; Ortiz, J; Remick, SC | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Deshpande, HA; Roman, S; Sosa, JA | 1 |
3 review(s) available for combretastatin and Cancer of the Thyroid
| Article | Year |
|---|---|
Myocardial stunning following combined modality combretastatin-based chemotherapy: two case reports and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bibenzyls; Carcinoma; Diagnostic Imaging; Electrocardiography; Female; Humans; Myocardial Stunning; Thyroid Neoplasms; Troponin I | 2009 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
New targeted therapies and other advances in the management of anaplastic thyroid cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bibenzyls; Clinical Trials as Topic; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2013 |